According to VGX Pharmaceuticals, VGX-1027 is the first of a new class of immune modulators that inhibits the production of several proinflammatory cytokines, which are responsible for the damaging effects of inflammatory diseases. VGX-1027 is an orally active, small molecule compound that has shown preclinical efficacy against rheumatoid arthritis (RA) and type 1 diabetes (T1D).
VGX will conduct single ascending dose and multiple ascending dose in its Phase I studies on VGX-1027. The company said that, upon successful completion, the results from these studies will satisfy FDA requirements to commence two Phase II studies, one for RA patients, to be conducted by VGX Pharmaceuticals, and one for T1D patients, to be conducted by its affiliate, VGX International.